

**SINGAPORE  
BIOTECH INVEST**

**21-22 March 2017**

Singapore Exchange (SGX)

**HONG KONG  
BIOTECH INVEST**

**23-24 March 2017**

KPMG Hong Kong

**AUSTRALIA-CHINA  
BIOTECH INVEST**

**27-28 March 2017**

Shanghai Marriott Hotel City Centre

## **Fivephusion Pty Ltd Company Profile**

Fivephusion Pty Ltd is an inventor owned oncology company. It has just completed a phase 1b/2a clinical trial of Deflexifol, its widely patented pH neutral, "all-in-one" injectable solution of 5-Fluorouracil (5-FU) and its biomodulator Leucovorin (LV). Simultaneous administration of 5-FU and LV is not feasible due to their chemical incompatibility, so the maximum possible interaction for benefit is not achieved. Deflexifol maximises their interaction. Deflexifol can replace these drugs in most standard of care regimens (FOLFOX, FOLFIRI and derivative regimens) for metastatic colorectal cancer. Other indications include other GI, breast and head and neck cancer.

The Deflexifol phase 1b/2a trial demonstrated greatly reduced toxicity at higher tolerated doses. Disease control was seen in 69% of patients, despite most having failed previous 5-FU regimens. Higher and concomitant dosing of 5-FU with LV in Deflexifol make increased efficacy highly likely.

Deflexifol has the capacity to become the new standard fluoropyrimidine in a market with global sales exceeding \$1 billion each year.

Deflexifol was confirmed by the FDA at a pre-IND meeting as being suitable for a Section 505(b)(2) NDA.

Fivephusion is planning a phase 2/3 trial to measure these improvements.

Fivephusion seeks to out-licence or partner to commercialize Deflexifol.